A coherent, modular technology stack — synthesis, formulation, and analytics that were designed to work together. Each module is phase-flexible and built to scale without re-engineering.
Our IVT workflows convert linearized DNA templates into high-quality mRNA at yields tuned for each construct. Reaction conditions, nucleotide ratios, and enzyme selection are optimized to maximize full-length transcript while minimizing aberrant species and double-stranded RNA byproducts.
Controlled enzymatic linearization produces a clean, run-off-ready template with defined ends. In-process identity and completeness checks ensure the template entering IVT is consistent batch to batch.
We offer both co-transcriptional and enzymatic capping strategies to achieve high cap-1 efficiency for translation and immune profile, paired with defined, homogeneous poly(A) tails — by template encoding or enzymatic addition.
Multi-step purification trains remove residual enzymes, nucleotides, template DNA, and truncated species. Chromatographic and membrane-based steps are combined and scaled to deliver high-purity drug substance at every phase.
FluxMix™ is our microfluidic mixing platform for lipid nanoparticle formulation. By precisely controlling mixing geometry and flow dynamics, it produces nanoparticles with tight size distribution and high encapsulation efficiency — and, critically, it holds those attributes constant as you scale from milligrams to multi-gram batches.
As the field moves past first-generation mRNA, our platform moves with it. We support emerging constructs end-to-end, not just at the bench.
saRNA constructs that encode their own replication machinery for lower-dose, longer-duration expression — supported through synthesis, purification, and LNP delivery.
circRNA for enhanced stability and durable expression, with purification and analytics tuned to the unique structural demands of closed-loop transcripts.
Incorporation of modified nucleosides to tune translation and the innate immune response, with capping and purification optimized for each chemistry.
Generic biologics assays don't capture what matters for mRNA and lipid nanoparticles. Our analytical scientists develop and qualify phase-appropriate, modality-specific methods that give you the data regulators expect.
Whether it's conventional mRNA, saRNA, or circRNA, our scientists will tell you exactly how our platform fits your molecule.